Tatjana Welzel1,2, Carolyn Winskill3, Nancy Zhang3, Andreas Woerner4, Marc Pfister5,3. 1. Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031, Basel, Switzerland. Tatjana.Welzel@ukbb.ch. 2. Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland. Tatjana.Welzel@ukbb.ch. 3. Integrated Drug Development, Certara LP, Princeton, NJ, USA. 4. Paediatric Rheumatology, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland. 5. Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, Spitalstrasse 33, CH 4031, Basel, Switzerland.
Abstract
BACKGROUND: Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients. METHODS: A systematic literature search for randomized clinical trials (RCTs) in PiRD treated with bDMARDs/JAK inhibitors was conducted on Medline, clinicaltrials.gov , clinicaltrialsregister.eu and conference abstracts as of July 2020. RCTs were included if (i) patients were aged ≤20 years, (ii) patients had a predefined rheumatic diagnosis and (iii) RCT reported predefined outcomes. Selected studies were excluded in case of (i) observational or single arm study or (ii) sample size ≤5 patients. Study characteristics were extracted. RESULTS: Out of 608 screened references, 65 references were selected, reporting 35 unique RCTs. All 35 RCTs reported efficacy while 34/3 provided safety outcomes and 16/35 provided pharmacokinetic data. The most common investigated treatments were TNF inhibitors (60%), IL-1 inhibitors (17%) and IL-6 inhibitors (9%). No RCTs with published results were identified for baricitinib, brodalumab, certolizumab pegol, guselkumab, risankizumab, rituximab, sarilumab, secukinumab, tildrakizumab, or upadacitinib. In patients with juvenile idiopathic arthritis (JIA) 25/35 RCTs were conducted. The remaining 10 RCTs were performed in non-JIA patients including plaque psoriasis, Kawasaki Disease, systemic lupus erythematosus and non-infectious uveitis. In JIA-RCTs, the control arm was mainly placebo and the concomitant treatments were either methotrexate, non-steroidal anti-inflammatory drugs (NSAID) or corticosteroids. Non-JIA patients mostly received NSAID. There are ongoing trials investigating abatacept, adalimumab, baricitinib, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, risankizumab, secukinumab, tofacitinib and tildrakizumab. CONCLUSION: Despite the FDA Modernization Act and support of major paediatric rheumatology networks, such as the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO), which resulted in drug approval for PiRD indications, there are limited RCTs in PiRD patients. As therapy response is influenced by age-dependent changes, pharmacokinetic processes and disease course it is important to consider developmental changes in bDMARDs/JAK inhibitor use in PiRD patients. As such it is critical to collaborate and conduct international RCTs to appropriately investigate and characterize efficacy, safety and pharmacokinetics of bDMARDs/JAK inhibitors in paediatric rheumatology.
BACKGROUND: Biologic disease modifying antirheumatic drugs (bDMARDs) and Janus Kinase (JAK) inhibitors are prescribed in adult and paediatric rheumatology. Due to age-dependent changes, disease course, and pharmacokinetic processes paediatric patients with inflammatory rheumatic diseases (PiRD) differ from adult rheumatology patients. METHODS: A systematic literature search for randomized clinical trials (RCTs) in PiRD treated with bDMARDs/JAK inhibitors was conducted on Medline, clinicaltrials.gov , clinicaltrialsregister.eu and conference abstracts as of July 2020. RCTs were included if (i) patients were aged ≤20 years, (ii) patients had a predefined rheumatic diagnosis and (iii) RCT reported predefined outcomes. Selected studies were excluded in case of (i) observational or single arm study or (ii) sample size ≤5 patients. Study characteristics were extracted. RESULTS: Out of 608 screened references, 65 references were selected, reporting 35 unique RCTs. All 35 RCTs reported efficacy while 34/3 provided safety outcomes and 16/35 provided pharmacokinetic data. The most common investigated treatments were TNF inhibitors (60%), IL-1 inhibitors (17%) and IL-6 inhibitors (9%). No RCTs with published results were identified for baricitinib, brodalumab, certolizumab pegol, guselkumab, risankizumab, rituximab, sarilumab, secukinumab, tildrakizumab, or upadacitinib. In patients with juvenile idiopathic arthritis (JIA) 25/35 RCTs were conducted. The remaining 10 RCTs were performed in non-JIA patients including plaque psoriasis, Kawasaki Disease, systemic lupus erythematosus and non-infectious uveitis. In JIA-RCTs, the control arm was mainly placebo and the concomitant treatments were either methotrexate, non-steroidal anti-inflammatory drugs (NSAID) or corticosteroids. Non-JIA patients mostly received NSAID. There are ongoing trials investigating abatacept, adalimumab, baricitinib, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, risankizumab, secukinumab, tofacitinib and tildrakizumab. CONCLUSION: Despite the FDA Modernization Act and support of major paediatric rheumatology networks, such as the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO), which resulted in drug approval for PiRD indications, there are limited RCTs in PiRD patients. As therapy response is influenced by age-dependent changes, pharmacokinetic processes and disease course it is important to consider developmental changes in bDMARDs/JAK inhibitor use in PiRD patients. As such it is critical to collaborate and conduct international RCTs to appropriately investigate and characterize efficacy, safety and pharmacokinetics of bDMARDs/JAK inhibitors in paediatric rheumatology.
Authors: Ross E Petty; Taunton R Southwood; Prudence Manners; John Baum; David N Glass; Jose Goldenberg; Xiaohu He; Jose Maldonado-Cocco; Javier Orozco-Alcala; Anne-Marie Prieur; Maria E Suarez-Almazor; Patricia Woo Journal: J Rheumatol Date: 2004-02 Impact factor: 4.666
Authors: Angelo Ravelli; Alessandro Consolaro; Gerd Horneff; Ronald M Laxer; Daniel J Lovell; Nico M Wulffraat; Jonathan D Akikusa; Sulaiman M Al-Mayouf; Jordi Antón; Tadej Avcin; Roberta A Berard; Michael W Beresford; Ruben Burgos-Vargas; Rolando Cimaz; Fabrizio De Benedetti; Erkan Demirkaya; Dirk Foell; Yasuhiko Itoh; Pekka Lahdenne; Esi M Morgan; Pierre Quartier; Nicolino Ruperto; Ricardo Russo; Claudia Saad-Magalhães; Sujata Sawhney; Christiaan Scott; Susan Shenoi; Joost F Swart; Yosef Uziel; Sebastiaan J Vastert; Josef S Smolen Journal: Ann Rheum Dis Date: 2018-04-11 Impact factor: 19.103
Authors: N Ruperto; A Ravelli; F Falcini; L Lepore; A Buoncompagni; V Gerloni; M Bardare; E Cortis; F Zulian; M L Sardella; C Giovanni Strano; M Alessio; M G Alpigiani; D Migliavacca; A Pistorio; S Viola; A Martini Journal: Rheumatology (Oxford) Date: 1999-02 Impact factor: 7.580
Authors: Claas H Hinze; Prasad T Oommen; Frank Dressler; Andreas Urban; Frank Weller-Heinemann; Fabian Speth; Elke Lainka; Jürgen Brunner; Heike Fesq; Dirk Foell; Wolfgang Müller-Felber; Ulrich Neudorf; Christoph Rietschel; Tobias Schwarz; Ulrike Schara; Johannes-Peter Haas Journal: Pediatr Rheumatol Online J Date: 2018-06-25 Impact factor: 3.054
Authors: Lina N Zaripova; Angela Midgley; Stephen E Christmas; Michael W Beresford; Eileen M Baildam; Rachel A Oldershaw Journal: Pediatr Rheumatol Online J Date: 2021-08-23 Impact factor: 3.413
Authors: Klervi Golhen; Carolyn Winskill; Martin Theiler; Michael Buettcher; Yu-Hsin Yeh; Nancy Zhang; Tatjana Welzel; Marc Pfister Journal: Front Med (Lausanne) Date: 2022-09-26